BioXcel Therapeutics Inc (BTAI) Stock AnalysisBTAIBioXcel Therapeutics Inc

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

BioXcel Therapeutics Inc is not a good buy right now due to its significant financial distress and recent bankruptcy filing. The current price is $0.0739, which reflects a staggering 95.65% decline year-to-date. Additionally, the company has reported a gross margin of only 87.91% in the most recent quarter, indicating severe operational challenges. The primary risk is its recent bankruptcy filing, which raises concerns about the company's ability to continue operations and meet obligations.

4 analysts cover BTAI: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 5.50.